{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04640987",
            "orgStudyIdInfo": {
                "id": "IRB-58549"
            },
            "secondaryIdInfos": [
                {
                    "id": "BMT 367 - T-allo10 Alpha Beta",
                    "type": "OTHER",
                    "domain": "Stanford University"
                }
            ],
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback",
            "officialTitle": "Phase 1/1b Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR \u03b1\u03b2+ T-cell/ CD19+ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (\u03b1\u03b2 Depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "stem-cell-transplant-from-donors-after-alpha-beta-cell-depletion-in-children-and-adults-with-t-cells-addback"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-01-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-17",
            "studyFirstSubmitQcDate": "2020-11-17",
            "studyFirstPostDateStruct": {
                "date": "2020-11-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Alice Bertaina",
                "investigatorTitle": "Associate Professor of Pediatrics",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Porteus, Matthew, MD",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "California Institute for Regenerative Medicine (CIRM)",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety of a cell therapy, T-allo10, after \u03b1\u03b2depleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).\n\nThe primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of \u03b1\u03b2depleted-HSCT in children and young adults with hematologic malignancies.\n\nA Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of \u03b1\u03b2depleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution.\n\nAll participants on this study must be enrolled on another study: NCT04249830"
        },
        "conditionsModule": {
            "conditions": [
                "Hematologic Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 22,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 1 X 10\\^5/kg",
                    "interventionNames": [
                        "Biological: Allogeneic Stem Cell Transplant",
                        "Device: CliniMACS Prodigy System",
                        "Drug: T-allo10 cells addback"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 3 X 10\\^5/kg",
                    "interventionNames": [
                        "Biological: Allogeneic Stem Cell Transplant",
                        "Device: CliniMACS Prodigy System",
                        "Drug: T-allo10 cells addback"
                    ]
                },
                {
                    "label": "Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "The participant will undergo a alpha-beta depleted stem cell transplant using donor cells. The participant's cells will then be manipulated via a T-allo10 cell addback to reach a dose level of 1 X 10\\^6/kg",
                    "interventionNames": [
                        "Biological: Allogeneic Stem Cell Transplant",
                        "Device: CliniMACS Prodigy System",
                        "Drug: T-allo10 cells addback"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Allogeneic Stem Cell Transplant",
                    "description": "The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "CliniMACS Prodigy System",
                    "description": "Device used for production of T-allo10 cells.",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "T-allo10 cells addback",
                    "description": "T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with myeloid engraftment after T-allo10",
                    "timeFrame": "Through day 35 (+/- 7 days) after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants without grade II aGvHD requiring steroids after T-allo10",
                    "timeFrame": "Through day 35 (+/- 7 days) after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants without grade III/IV aGvHD after T-allo10",
                    "timeFrame": "Through day 35 (+/- 7 days) after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants with absence of dose-limiting toxicity (DLT) 28 days following the infusion of T-allo10 given at the recommended phase 2 dose (RP2D)",
                    "timeFrame": "Assessed at 28 days (after infusion of T-allo10)"
                },
                {
                    "measure": "Number of participants who reach immune reconstitution (IR) threshold",
                    "description": "IR (a surrogate of reduced risk of leukemia recurrence) is defined reaching the threshold of 50CD3+CD4+T-cells/\u00b5l by Day+60(+/-10days).",
                    "timeFrame": "Through Day 60 (+/- 10 days) after infusion of T-allo10"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with \u2265grade 3 adverse event related to T-allo10 infusion",
                    "timeFrame": "Through 1 year after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants with grade II-IV aGvHD",
                    "timeFrame": "Assessed at day 90 after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants with grade III-IV aGvHD",
                    "timeFrame": "Assessed at day 180 after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants with cGvHD",
                    "timeFrame": "Assessed at 1 year after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Leukemia-free survival",
                    "description": "Leukemia-free survival defined as at the time of enrollment to disease relapse or death from any cause.",
                    "timeFrame": "Assessed at 1 year after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Number of participants with disease relapse",
                    "description": "Disease relapse is defined as the return of signs and symptoms of a disease after a remission.",
                    "timeFrame": "Assessed at 1 year after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Non-relapse mortality",
                    "timeFrame": "Assessed at Day 90 after \u03b1\u03b2depleted-HSCT"
                },
                {
                    "measure": "Non-relapse mortality",
                    "timeFrame": "Assessed at 1 year after \u03b1\u03b2depleted-HSCT"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria prior to enrollment:\n\n* 1. Age \\> 1 months (with minimum weight of 10 Kg) and \\< 45 years.\n* 2. Patients deemed eligible for allogeneic HSCT under the originating study, NCT 04249830\n* 3. Patients with life-threatening hematological malignancies for which HSCT has been recommended:\n\n  1. High-risk ALL in 1st CR, ALL in 2nd or subsequent CR;\n  2. High-risk AML in 1st CR, AML in 2nd or subsequent CR;\n  3. Myelodysplastic syndrome;\n  4. JMML (Juvenile myelomonocytic leukemia);\n  5. Non-Hodgkin lymphomas in 2nd or subsequent CR;\n  6. Other hematologic malignancies eligible for stem cell transplantation per institutional standard.\n* 4. All subjects \u2265 18 years of age must be able to give informed consent, or adults lacking capacity to consent must have a LAR available to provide consent. For subjects \\<18 years old their LAR (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those \\> 7 years of age, when appropriate.\n\nInclusion criteria prior to T-allo10 infusion:\n\n1. Patient already received \u03b1\u03b2depleted-HSCT and has myeloid engraftment.\n2. Absence of active grade II aGvHD requiring \\>0.5 mg/Kg of steroids or any diagnosis of grade III/IVaGvHD.\n\nExclusion Criteria prior to MNC collection for Tallo-10 manufacturing.:\n\n1. Not eligible to receive HSCT on NCT04249830\n2. Received another investigational agent within 30 days of enrollment.\n3. Pregnancy (positive serum or urine beta-HCG) within 7 days of MNC donation.\n4. Patient or donor is not willing or able to undergo an additional non-mobilized apheresis for collection of MNC prior to donation of cells for participation in NCT04249830.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Month",
            "maximumAge": "45 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Alice Bertaina, MD, PhD",
                    "affiliation": "Associate Professor of Pediatrics, Stem Cell Transplantation",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Lucile Packard Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Natalie Pukesh",
                            "role": "CONTACT",
                            "phone": "650-724-4622",
                            "email": "scgt_clinical_trials_office@lists.stanford.edu"
                        },
                        {
                            "name": "Rosa Bacchetta, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David Shyr, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Rajni Agarwal, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "asFound": "Hematologic Diseases",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}